Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Here are four payer-related headlines in the last two weeks for ASCs to know. 1. Medical practices and hospitals saw claims denials increase and prior authorization denials decrease in 2024, according ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Plus, peek inside Raleigh’s newest data center, a Duke researcher reflects on her canceled federal grant amid buyouts, and ...

Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some ...

The U.S. Food and Drug Administration has cracked down on compounded drugs, which were readily available while the patented ...